Literature DB >> 30573046

The challenging task of enumerating blasts in the bone marrow.

Aaron Hodes1, Katherine R Calvo2, Alina Dulau2, Irina Maric2, Junfeng Sun3, Raul Braylan4.   

Abstract

Enumeration of blasts in the bone marrow is critical for diagnostic, prognostic, and therapeutic response evaluation in myelodysplastic syndromes, myeloproliferative neoplasms and acute leukemias. However, few studies have examined the accuracy and precision of marrow blast counting using standard microscopic procedures. In our study, 4 experienced hematopathologists evaluated blast percentages in marrow using either differential counts on aspirate smears or visual estimates on CD34-stained trephine biopsies. Results of an independent observer's manual counts of individual labeled and unlabeled cells performed on high resolution digital images of CD34-stained trephine biopsies were designated as the "Digital Reference." Hematopathologists' blast counts showed excellent interobserver reproducibility, but the counts in smears and trephine biopsies correlated poorly with each other. Compared to the Digital Reference, both smear and trephine evaluations showed positive bias and high variability. The biopsy showed less variability but higher positive bias relative to the smears, indicating that counts were overestimated more in the hematopathologists' biopsy evaluation. Flow cytometric counts correlated well with the Digital Reference, and cases with high blast count generally showed worse cytogenetic findings. Our results demonstrate the need for better counting methods if significant decisions are made based on microscopic enumeration of blasts. Further efforts should be made to develop markers to better define blast cells and perhaps incorporate automated digital imaging technologies to enumerate them. Also, consideration should be given to quantifying blasts per marrow area in biopsies instead of per nucleated cells.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Blast count; Bone marrow; Myelodysplastic syndrome

Mesh:

Year:  2018        PMID: 30573046     DOI: 10.1053/j.seminhematol.2018.07.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Authors:  Megan Othus; Robert Peter Gale; Christopher S Hourigan; Roland B Walter
Journal:  Bone Marrow Transplant       Date:  2019-10-30       Impact factor: 5.483

Review 3.  "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?

Authors:  Xueyan Chen; Jonathan R Fromm; Kikkeri N Naresh
Journal:  Leukemia       Date:  2022-01-19       Impact factor: 11.528

4.  Detection of Metastatic Tumor Cells in the Bone Marrow Aspirate Smears by Artificial Intelligence (AI)-Based Morphogo System.

Authors:  Pu Chen; Run Chen Xu; Nan Chen; Lan Zhang; Li Zhang; Jianfeng Zhu; Baishen Pan; Beili Wang; Wei Guo
Journal:  Front Oncol       Date:  2021-09-27       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.